Activated PKR inhibits pancreatic β-cell proliferation through sumoylation-dependent stabilization of P53

Molecular Immunology

Volumn 68, Issue 2, 2015, Pages 341-349

  Song, Ying ^a   Wan, XiaoMeng ^b   Gao, LiLi ^b   Pan, Yi ^b   Xie, WeiPing ^a   Wang, Hong ^a   Guo, Jun ^b  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Ceramide; P53; Pancreatic cell; PKR; Proliferation; Sumoylation

Indexed keywords

1H BENZIMIDAZOLE1 ETHANOL,2,3 DIHYDRO 2 IMINOA (PHENOXYMETHYL) 3 (PHENYLMETHYL) ,MONOHYDROCHLORIDE; CERAMIDE; ENZYME ACTIVATOR; FUMONISIN B1; PROTEIN KINASE R; PROTEIN P53; PROTEIN UBC9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BENZIMIDAZOLE DERIVATIVE; LUCIFERASE; PROTEIN BINDING; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN-CONJUGATING ENZYME UBC9;

ARTICLE; CELL PROLIFERATION; CELL STRESS; CONTROLLED STUDY; DRUG SYNTHESIS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INVESTIGATIVE PROCEDURES; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SUMOYLATION; UPREGULATION; ANIMAL; CYTOLOGY; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; PROTEIN STABILITY; REPORTER GENE; TUMOR CELL LINE;

ANIMALS; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; CERAMIDES; EIF-2 KINASE; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENES, REPORTER; INSULIN-SECRETING CELLS; LUCIFERASES; MICE; PROTEIN BINDING; PROTEIN STABILITY; SIGNAL TRANSDUCTION; SUMOYLATION; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-CONJUGATING ENZYMES;

EID: 84955708626     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.09.007     Document Type: Article

References (87)

1. Alejandro E.U., Gregg B., Blandino-Rosano M., Cras-Meneur C., Bernal-Mizrachi E. Natural history of beta-cell adaptation and failure in type 2 diabetes. Mol. Aspects Med. 2015, 42:19-41.
2. Alontaga A.Y., Bobkova E., Chen Y. Biochemical analysis of protein SUMOylation. Curr. Protoc. Mol. Biol. 2012, 29. Chapter 10: Unit10.
3. Ardestani S., Deskins D.L., Young P.P. Membrane TNF-alpha-activated programmed necrosis is mediated by Ceramide-induced reactive oxygen species. J. Mol. Signal. 2013, 8(1):12.
4. Barth B.M., Gustafson S.J., Hankins J.L., Kaiser J.M., Haakenson J.K., Kester M., Kuhn T.B. Ceramide kinase regulates TNFalpha-stimulated NADPH oxidase activity and eicosanoid biosynthesis in neuroblastoma cells. Cell Signal. 2012, 24(6):1126-1133.
5. Bennett R.L., Blalock W.L., Abtahi D.M., Pan Y., Moyer S.A., May W.S. RAX, the PKR activator, sensitizes cells to inflammatory cytokines, serum withdrawal, chemotherapy, and viral infection. Blood 2006, 108(3):821-829.
6. Bennett R.L., Pan Y., Christian J., Hui T., May W.S. The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and activation, leading to G(1) arrest. Cell Cycle 2012, 11(2):407-417.
7. Blandino-Rosano M., Perez-Arana G., Mellado-Gil J.M., Segundo C., Aguilar-Diosdado M. Anti-proliferative effect of pro-inflammatory cytokines in cultured beta cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide-1. J. Mol. Endocrinol. 2008, 41(1):35-44.
8. Carvalho-Filho M.A., Carvalho B.M., Oliveira A.G., Guadagnini D., Ueno M., Dias M.M., Tsukumo D.M., Hirabara S.M., Reis L.F., Curi R., et al. Double-stranded RNA-activated protein kinase is a key modulator of insulin sensitivity in physiological conditions and in obesity in mice. Endocrinology 2012, 153(11):5261-5274.
9. Carvalho B.M., Oliveira A.G., Ueno M., Araujo T.G., Guadagnini D., Carvalho-Filho M.A., Geloneze B., Lima M.M., Pareja J.C., Carvalheira J.B., et al. Modulation of double-stranded RNA-activated protein kinase in insulin sensitive tissues of obese humans. Obesity (Silver Spring) 2013, 21(12):2452-2457.
10. Chen S.S., Jiang T., Wang Y., Gu L.Z., Wu H.W., Tan L., Guo J. Activation of double-stranded RNA-dependent protein kinase inhibits proliferation of pancreatic beta-cells. Biochem. Biophys. Res. Commun. 2014, 443(3):814-820.
11. Clemens M.J., Elia A. The double-stranded RNA-dependent protein kinase PKR: structure and function. J. Interferon Cytokine Res. 1997, 17(9):503-524.
12. Cuddihy A.R., Wong A.H., Tam N.W., Li S., Koromilas A.E. The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro. Oncogene 1999, 18(17):2690-2702.
13. Dai C., Gu W. p53 Post-translational modification: deregulated in tumorigenesis. Trends Mol. Med. 2010, 16(11):528-536.
14. Dedoussis G.V., Kaliora A.C., Panagiotakos D.B. Genes, diet and type 2 diabetes mellitus: a review. Rev. Diabet. Stud. 2007, 4(1):13-24.
15. DeFronzo R.A. Pathogenesis of type 2 diabetes mellitus. Med. Clin. N. Am. 2004, 88(4):787-835. ix.
16. Dixit D., Sharma V., Ghosh S., Mehta V.S., Sen E. Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFalpha)-induced apoptosis through SIRT1 inhibition. Cell Death Dis. 2012, 3:e271.
17. Du M.J., Zhang H.K., He A.J., Chang Y.S., Yang Y., Wang Y., Zhang C.Z., Cao Y. Selection of peptide inhibitors for double-stranded RNA-dependent protein kinase PKR. Biochemistry (Mosc) 2013, 78(11):1254-1262.
18. Garcia M.A., Gil J., Ventoso I., Guerra S., Domingo E., Rivas C., Esteban M. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol. Mol. Biol. Rev. 2006, 70(4):1032-1060.
19. Gastaldelli A. Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 2011, 93(Suppl 1):S60-S65.
20. Gao L., Tang W., Ding Z., Wang D., Qi X., Wu H., Guo J. Protein-binding function of rna-dependent protein kinase promotes proliferation through TRAF2/RIP1/NF-κB/c-Myc pathway in pancreatic β cells. Mol. Med. 2015, 21:154-166.
21. Gaur P., Munjhal A., Lal S.K. Influenza virus and cell signaling pathways. Med. Sci. Monit. 2011, 17(6):RA148-RA154.
22. Ghosh N., Patel N., Jiang K., Watson J.E., Cheng J., Chalfant C.E., Cooper D.R. Ceramide-activated protein phosphatase involvement in insulin resistance via Akt, serine/arginine-rich protein 40, and ribonucleic acid splicing in L6 skeletal muscle cells. Endocrinology 2007, 148(3):1359-1366.
23. Gilbert S.J., Duance V.C., Mason D.J. Tumour necrosis factor alpha up-regulates protein kinase R (PKR)-activating protein (PACT) and increases phosphorylation of PKR and eukaryotic initiation factor 2-alpha in articular chondrocytes. Biochem. Soc. Tran.s 2002, 30(Pt 6):886-889.
24. Gilbert S.J., Duance V.C., Mason D.J. Does protein kinase R mediate TNF-alpha- and ceramide-induced increases in expression and activation of matrix metalloproteinases in articular cartilage by a novel mechanism?. Arthritis Res. Ther. 2004, 6(1):R46-R55.
25. Goldstein B.J. Insulin resistance as the core defect in type 2 diabetes mellitus. Am. J. Cardiol. 2002, 90(5A):3G-10G.
26. Gregor M.F., Hotamisligil G.S. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 2011, 29:415-445.
27. Gu L., Huang B., Shen W., Gao L., Ding Z., Wu H., Guo J. Early activation of nSMase2/ceramide pathway in astrocytes is involved in ischemia-associated neuronal damage via inflammation in rat hippocampi. J. Neuroinflammation 2013, 10:109.
28. Guo J., Qian Y., Xi X., Hu X., Zhu J., Han X. Blockage of ceramide metabolism exacerbates palmitate inhibition of pro-insulin gene expression in pancreatic beta-cells. Mol. Cell Biochem. 2010, 338(1-2):283-290.
29. Haus J.M., Kashyap S.R., Kasumov T., Zhang R., Kelly K.R., Defronzo R.A., Kirwan J.P. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 2009, 58(2):337-343.
30. Hirohama M., Kumar A., Fukuda I., Matsuoka S., Igarashi Y., Saitoh H., Takagi M., Shin-ya K., Honda K., Kondoh Y., et al. Spectomycin B1 as a novel SUMOylation inhibitor that directly binds to SUMO E2. ACS Chem. Biol. 2013, 8(12):2635-2642.
31. Hong J., Gu W.Q., Zhang Y.F., Yang Y.S., Shen C.F., Xu M., Li X.Y., Wang W.Q., Ning G. The interplay of insulin resistance and beta-cell dysfunction involves the development of type 2 diabetes in Chinese obeses. Endocrine 2007, 31(2):93-99.
32. Hoshino A., Ariyoshi M., Okawa Y., Kaimoto S., Uchihashi M., Fukai K., Iwai-Kanai E., Ikeda K., Ueyama T., Ogata T., et al. Inhibition of p53 preserves Parkin-mediated mitophagy and pancreatic beta-cell function in diabetes. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(8):3116-3121.
33. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444(7121):860-867.
34. Hotamisligil G.S. Endoplasmic reticulum stress and inflammation in obesity and type 2 diabetes. Novartis Found Symp. 2007, 286:86-94. discussion 94-8, 162-3, 196-203.
35. Hotamisligil G.S., Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat. Rev. Immunol. 2008, 8(12):923-934.
36. Hu W., Hofstetter W., Wei X., Guo W., Zhou Y., Pataer A., Li H., Fang B., Swisher S.G. Double-stranded RNA-dependent protein kinase-dependent apoptosis induction by a novel small compound. J. Pharmacol. Exp. Ther. 2009, 328(3):866-872.
37. Ishizuka N., Yagui K., Tokuyama Y., Yamada K., Suzuki Y., Miyazaki J., Hashimoto N., Makino H., Saito Y., Kanatsuka A. Tumor necrosis factor alpha signaling pathway and apoptosis in pancreatic beta cells. Metabolism 1999, 48(12):1485-1492.
38. Janikiewicz J., Hanzelka K., Kozinski K., Kolczynska K., Dobrzyn A. Islet beta-cell failure in type 2 diabetes-within the network of toxic lipids. Biochem. Biophys. Res. Commun. 2015, 460(3):491-496.
39. Karehed K., Dimberg A., Dahl S., Nilsson K., Oberg F. IFN-gamma-induced upregulation of Fcgamma-receptor-I during activation of monocytic cells requires the PKR and NFkappaB pathways. Mol. Immunol. 2007, 44(4):615-624.
40. Kasumov T., Solomon T.P., Hwang C., Huang H., Haus J.M., Zhang R., Kirwan J.P. Improved insulin sensitivity after exercise training is linked to reduced plasma C14:0 ceramide in obesity and type 2 diabetes. Obesity (Silver Spring) 2015, 23(7):1414-1421.
41. Kelpe C.L., Moore P.C., Parazzoli S.D., Wicksteed B., Rhodes C.J., Poitout V. Palmitate inhibition of insulin gene expression is mediated at the transcriptional level via ceramide synthesis. J. Biol. Chem. 2003, 278(32):30015-30021.
42. Koch L. Metabolism: DNA double-strand breaks and p53 activity in beta-cell failure. Nat. Rev. Endocrinol. 2014, 10(3):126.
43. Lang F., Ullrich S., Gulbins E. Ceramide formation as a target in beta-cell survival and function. Expert Opin. Ther. Targets 2011, 15(9):1061-1071.
44. Larsen M.O. Beta-cell function and mass in type 2 diabetes. Dan. Med. Bull. 2009, 56(3):153-164.
45. Lin J.Y., Ohshima T., Shimotohno K. Association of Ubc9, an E2 ligase for SUMO conjugation, with p53 is regulated by phosphorylation of p53. FEBS Lett. 2004, 573(1-3):15-18.
46. Linnemann A.K., Baan M., Davis D.B. Pancreatic beta-cell proliferation in obesity. Adv. Nutr. 2014, 5(3):278-288.
47. Liu J.J., Raynal S., Bailbe D., Gausseres B., Carbonne C., Autier V., Movassat J., Kergoat M., Portha B. Expression of the kynurenine pathway enzymes in the pancreatic islet cells. Activation by cytokines and glucolipotoxicity. Biochim. Biophys. Acta 2015, 1852(5):980-991.
48. Liu X.M., Yang F.F., Yuan Y.F., Zhai R., Huo L.J. SUMOylation of mouse p53b by SUMO-1 promotes its pro-apoptotic function in ovarian granulosa cells. PLoS One 2013, 8(5):e63680.
49. Majumder M., Mitchell D., Merkulov S., Wu J., Guan B.J., Snider M.D., Krokowski D., Yee V.C., Hatzoglou M. Residues required for phosphorylation of translation initiation factor eIF2alpha under diverse stress conditions are divergent between yeast and human. Int. J. Biochem. Cell Biol. 2015, 59:135-141.
50. Manukyan L., Ubhayasekera S.J., Bergquist J., Sargsyan E., Bergsten P. Palmitate-induced impairments of beta-cell function are linked with generation of specific ceramide species via acylation of sphingosine. Endocrinology 2015, 156(3):802-812.
51. Marchal J.A., Lopez G.J., Peran M., Comino A., Delgado J.R., Garcia-Garcia J.A., Conde V., Aranda F.M., Rivas C., Esteban M., et al. The impact of PKR activation: from neurodegeneration to cancer. FASEB J. 2014, 28(5):1965-1974.
52. Marchetti P., Bugliani M., Boggi U., Masini M., Marselli L. The pancreatic beta cells in human type 2 diabetes. Adv. Exp. Med. Biol. 2012, 771:288-309.
53. Marchetti P., Dotta F., Lauro D., Purrello F. An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment. Regul. Pept. 2008, 146(1-3):4-11.
54. Martinez T.N., Chen X., Bandyopadhyay S., Merrill A.H., Tansey M.G. Ceramide sphingolipid signaling mediates Tumor Necrosis Factor (TNF)-dependent toxicity via caspase signaling in dopaminergic neurons. Mol. Neurodegener. 2012, 7:45.
55. Matsukura S., Kokubu F., Kurokawa M., Kawaguchi M., Ieki K., Kuga H., Odaka M., Suzuki S., Watanabe S., Homma T., et al. Role of RIG-I, MDA-5, and PKR on the expression of inflammatory chemokines induced by synthetic dsRNA in airway epithelial cells. Int. Arch. Allergy Immunol. 2007, 14:80-83.
56. Melchior F., Hengst L. SUMO-1 and p53. Cell Cycle 2002, 1(4):245-249.
57. Meng Z.X., Nie J., Ling J.J., Sun J.X., Zhu Y.X., Gao L., Lv J.H., Zhu D.Y., Sun Y.J., Han X. Activation of liver X receptors inhibits pancreatic islet beta cell proliferation through cell cycle arrest. Diabetologia 2009, 52(1):125-135.
58. Mezza T., Kulkarni R.N. The regulation of pre- and post-maturational plasticity of mammalian islet cell mass. Diabetologia 2014, 57(7):1291-1303.
59. Mohideen F., Capili A.D., Bilimoria P.M., Yamada T., Bonni A., Lima C.D. A molecular basis for phosphorylation-dependent SUMO conjugation by the E2 UBC9. Nat. Struct. Mol. Biol. 2009, 16(9):945-952.
60. Muntner P., He J., Chen J., Fonseca V., Whelton P.K. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann. Epidemiol. 2004, 14(9):686-695.
61. Nakamura T., Arduini A., Baccaro B., Furuhashi M., Hotamisligil G.S. Small-molecule inhibitors of PKR improve glucose homeostasis in obese diabetic mice. Diabetes 2014, 63(2):526-534.
62. Nakamura T., Furuhashi M., Li P., Cao H., Tuncman G., Sonenberg N., Gorgun C.Z., Hotamisligil G.S. Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell 2010, 140(3):338-348.
63. Parkash J., Chaudhry M.A., Rhoten W.B. Tumor necrosis factor-alpha-induced changes in insulin-producing beta-cells. Anat. Rec. A Discov. Mol. Cell Evol. Biol. 2005, 286(2):982-993.
64. Quintana-Lopez L., Blandino-Rosano M., Perez-Arana G., Cebada-Aleu A., Lechuga-Sancho A., Aguilar-Diosdado M., Segundo C. Nitric oxide is a mediator of antiproliferative effects induced by proinflammatory cytokines on pancreatic beta cells. Mediat. Inflamm. 2013, 2013. 905175.
65. Ruvolo P.P. Ceramide regulates cellular homeostasis via diverse stress signaling pathways. Leukemia 2001, 15(8):1153-1160.
66. Ruvolo P.P., Gao F., Blalock W.L., Deng X., May W.S. Ceramide regulates protein synthesis by a novel mechanism involving the cellular PKR activator RAX. J. Biol. Chem. 2001, 276(15):11754-11758.
67. Sadler A.J., Williams B.R. Structure and function of the protein kinase R. Curr. Top Microbiol. Immunol. 2007, 316:253-292.
68. Schilling J.D., Machkovech H.M., He L., Sidhu R., Fujiwara H., Weber K., Ory D.S., Schaffer J.E. Palmitate and lipopolysaccharide trigger synergistic ceramide production in primary macrophages. J. Biol. Chem. 2013, 288(5):2923-2932.
69. Shimabukuro M., Zhou Y.T., Levi M., Unger R.H. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(5):2498-2502.
70. Sireesh D., Bhakkiyalakshmi E., Ramkumar K.M., Rathinakumar S., Jennifer P.S., Rajaguru P., Paulmurugan R. Targeting SUMOylation cascade for diabetes management. Curr. Drug Targets 2014, 15(12):1094-1106.
71. Sjoholm A. Cytokines inhibit proliferation and insulin secretion by clonal rat insulinoma cells (RINm5F) non-synergistically and in a pertussis toxin-insensitive manner. Immunol. Lett. 1991, 30(1):81-86.
72. Song I., Muller C., Louw J., Bouwens L. Regulating the Beta cell mass as a strategy for type-2 diabetes treatment. Curr. Drug Targets 2015, 16(5):516-524.
73. Sugiyama T., Gotou T., Moriyama K., Kajiura N., Hasegawa T., Tomida J., Takahashi K., Komatsu T., Ueda H., Sato K., et al. Mechanism of inhibition of lipopolysaccharide-induced interferon-beta production by 2-aminopurine. Mol. Immunol. 2012, 52(3-4):299-304.
74. Summers S.A. Ceramides in insulin resistance and lipotoxicity. Prog. Lipid Res. 2006, 45(1):42-72.
75. Symons J.D., Abel E.D. Lipotoxicity contributes to endothelial dysfunction: a focus on the contribution from ceramide. Rev. Endocr. Metab. Disord. 2013, 14(1):59-68.
76. Taylor S.S., Haste N.M., Ghosh G. PKR and eIF2alpha: integration of kinase dimerization, activation, and substrate docking. Cell 2005, 122(6):823-825.
77. Tornovsky-Babeay S., Dadon D., Ziv O., Tzipilevich E., Kadosh T., Schyr-Ben Haroush R., Hija A., Stolovich-Rain M., Furth-Lavi J., Granot Z., et al. Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in beta cells. Cell Metab. 2014, 19(1):109-121.
78. Tripathy D., Chavez A.O. Defects in insulin secretion and action in the pathogenesis of type 2 diabetes mellitus. Curr. Diab. Rep. 2010, 10(3):184-191.
79. Veret J., Coant N., Berdyshev E.V., Skobeleva A., Therville N., Bailbe D., Gorshkova I., Natarajan V., Portha B., Le StunffH. Ceramide synthase 4 and de novo production of ceramides with specific N-acyl chain lengths are involved in glucolipotoxicity-induced apoptosis of INS-1 beta-cells. Biochem. J. 2011, 438(1):177-189.
80. Wang Y., Wu H., Gao L., Chen S., Gu L., Ding Z., Guo J. Elevated toll-like receptor 3 inhibits pancreatic beta-cell proliferation through G1 phase cell cycle arrest. Mol. Cell Endocrinol. 2013, 377(1-2):112-122.
81. Westwick J.K., Bielawska A.E., Dbaibo G., Hannun Y.A., Brenner D.A. Ceramide activates the stress-activated protein kinases. J. Biol. Chem. 1995, 270(39):22689-22692.
82. Wu S.Y., Chiang C.M. p53 Sumoylation: mechanistic insights from reconstitution studies. Epigenetics 2009, 4(7):445-451.
83. Yabe D., Seino Y., Fukushima M., Seino S. Beta cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr. Diab. Rep. 2015, 15(6):602.
84. Yang C.C., Chung A., Ku C.Y., Brill L.M., Williams R., Wolf D.A. Systems analysis of the prostate tumor suppressor NKX3. 1 supports roles in DNA repair and luminal cell differentiation. F1000 Res. 2014, 3:115.
85. Zhang H., Zhang C. Vasoprotection by dietary supplements and exercise: role of TNFalpha signaling. Exp. Diabetes Res. 2012, 2012:972679.
86. Zhao X. Increase of beta cell mass by beta cell replication, but not neogenesis, in the maternal pancreas in mice. Endocr. J. 2014, 61(6):623-628.
87. Zinchuk V., Zinchuk O., Okada T. Quantitative colocalization analysis of multicolor confocal immunofluorescence microscopy images: pushing pixels to explore biological phenomena. Acta Histochem. Cytochem. 2007, 40(4):101-111.